Alumis Stock Soars to $20 in Record Timeframe Following Successful Plaque Psoriasis Breakthrough

GasGasGasBro · 2026-01-20T21:01:14+00:00

Alumis Inc.'s Envudeucitinib shows promising phase 3 trial results for plaque psoriasis, leading to a significant stock surge. Its precision targeting offers competitive advantages in a growing market, with an FDA application planned for 2025 and additional trials underway.

GasGasGasBro

2026-01-20 21:01:14

Abstract generation in progress

The Rally Behind the Numbers

Alumis Inc. (ALMS) just delivered what biotech investors call a dream scenario: positive clinical trial data that sent the stock from $5.52 to an intraday peak of $23 in roughly 60 days. The catalyst? Impressive results from its phase 3 ONWARD trials for Envudeucitinib, a next-generation oral TYK2 inhibitor designed to tackle immune-mediated skin conditions. The stock eventually settled at $22.11, reflecting sustained bullish momentum.

What Makes Envudeucitinib Stand Out

Envudeucitinib targets the root cause of plaque psoriasis by suppressing dysregulated IL-23 and IL-17 pathways—inflammatory drivers that trigger the painful, scaly skin patches affecting over 8 million U.S. adults. Unlike broader immune therapies, this TYK2 inhibitor class offers precision targeting with fewer off-target effects.

The ONWARD program tested Envudeucitinib across two parallel 24-week phase 3 trials. The headline numbers were compelling: approximately 65% of patients achieved PASI 90 (near-complete skin clearance) and over 40% hit PASI 100 (complete clearance) by week 24 on average. These metrics position the candidate as a serious contender in the plaque psoriasis space.

A Market With Room for Growth

The competitive landscape tells an interesting story. While multiple drug classes address plaque psoriasis—IL-23 inhibitors, IL-17 inhibitors, TNF-alpha blockers, and others—the TYK2 inhibitor class remains relatively sparse. Bristol Myers Squibb’s Sotyktu is currently the only FDA-approved TYK2 option in this indication, generating $170 million in 2023, $246 million in 2024, and approximately $206 million across the first nine months of 2025. The category’s limited competition creates differentiation opportunities for newcomers.

What’s Next

Alumis plans to submit a New Drug Application (NDA) to the FDA in H2 2025, with additional ONWARD trial details expected at upcoming medical conferences. A long-term extension study (ONWARD3) is tracking durability and safety in existing trial participants. Beyond plaque psoriasis, Envudeucitinib is also in phase 2b testing for systemic lupus erythematosus, with data anticipated in Q3 2026.

The momentum suggests investor confidence in both the clinical profile and commercial potential of this therapy candidate.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.